Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.
Saiju JacobHiroyuki MuraiKimiaki UtsugisawaRichard J NowakHeinz WiendlKenji P FujitaFanny O'BrienJames F HowardPublished in: Therapeutic advances in neurological disorders (2020)
REGAIN [ClinicalTrials.gov identifier: NCT01997229]; REGAIN open-label extension [ClinicalTrials.gov identifier: NCT02301624].